The implications of pharmacogenomics in oncology

Using the example of childhood ALL, the number of survivors treated with chemotherapy alone increased from 18% (1970-1979) to 54% (1990-1999) and the life expectancy increased over those 3 decades.3 These data underscore the need to use the right chemotherapy and the right amount of chemotherapy to...

Full description

Saved in:
Bibliographic Details
Published in:Bioimpacts 2023, Vol.13 (3), p.181-182
Main Author: Latimer, Jean J.
Format: Article
Language:English
Subjects:
Biomarkers
Cancer
Cancer therapies
Chemotherapy
Children
Clinical trials
DNA sequencing
Drugs
Genetic Information Nondiscrimination Act 2008-US
Life expectancy
Life span
Medicare
Mutation
Oncology
Patients
Pharmacogenomics
Point mutation
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Using the example of childhood ALL, the number of survivors treated with chemotherapy alone increased from 18% (1970-1979) to 54% (1990-1999) and the life expectancy increased over those 3 decades.3 These data underscore the need to use the right chemotherapy and the right amount of chemotherapy to prevent secondary cancers and cardiac issues in patients who are cured and live for decades after their treatment. Because of the use of standard of care regimens for newly diagnosed cancers, insurance companies and Medicare do not cover the cost of tumor or cancer cell sequencing. The Affordable Care Act based insurance has been known to cover the cost of cancer treatment, if a cancer predisposing gene mutation is found. The unresponsive patient groups in clinical trials are now frequently subjected to tumor DNA sequencing to attempt to explain why they did not respond to treatment. Because of this additional layer of information, clinical trials may not need to be as large as they have been historically.
ISSN:2228-5660
2228-5652
2228-5660
DOI:10.34172/bi.2023.27686